HUTCHMED

London: Wednesday, 13 August 2014: Nutrition Science Partners Limited (“NSP”), a 50/50 joint venture between Chi-Med and Nestlé Health Science SA, today announces that a planned interim analysis was conducted on NATRUL-3, the global Phase III in

Patient enrolment completion for fruquintinib's Phase II study in non-small cell lung cancer; Fruquintinib development moving rapidly in four parallel studies in non-small cell lung cancer, colorectal cancer and gastric cancer

Final Results for the year ended 31 December 2014

Hutchison Sinopharm and AstraZeneca China signed an exclusive distribution agreement on Seroquel® in China

Notice of Announcement of 2014 Final Results

Total Voting Rights

Blocklisting Six Monthly Return

Initiation of fruquintinib Phase III registration study in colorectal cancer

Director's Shareholding

Total Voting Rights

Drug R&D Update Briefing for Analysts and Investors on 17 October 2014

Chi-Med and Merck Serono sign co-promotion agreement

TR-1: Notification of major interest in shares

Patient enrolment completed ahead of schedule for fruquintinib's Phase II study in colorectal cancer

HMPL-004 NATRUL-3 interim analysis result

Interim Results for the Six Months Ended 30 June 2014

Total Voting Rights

Blocklisting Six Monthly Return

Notice of Announcement of 2014 Interim Results

Chi-Med Refinancing of Existing Loan Facility

Initiation of Phase I clinical trial of novel Syk Inhibitor HMPL - 523 for autoimmune diseases

Initiation of fruquintinib Phase II study in non-small cell lung cancer

Director's Shareholding

Exercise of Options

Chi-Med and Shanghai Traditional Chinese Medicine expand commercial cooperation

Initiation of AZD6094 (HMPL-504/volitinib) Global Phase II Study in Papillary Renal Cell Carcinoma

Phase I clinical data for selective VEGFR, c-Met and VEGFR/FGFR inhibitors to be presented at the 2014 ASCO Annual Meeting

Results of Annual General Meeting

Chi-Med and Sinopharm complete regulatory approval for the establishment of new China drug distribution and marketing Joint Venture

Presentations of volitinib and epitinib data at the 2014 AACR Annual Meeting

Initiation of fruquintinib Phase II study in colorectal cancer

2013 Annual Report and Notice of Annual General Meeting

Final Results for the year ended 31 December 2013

TR-1: Notification of major interest in shares

Notice of Announcement of 2013 Final Results

Blocklisting Six Monthly Return

Chi-Med and Sinopharm form China drug distribution and marketing joint venture

Director's Shareholding

Chi-Med's Pharmaceutical R&D Business - Analyst & Investor Briefing

Candidate Nomination of Novel Small-Molecule Therapy in Inflammation Triggers Milestone Payment From Janssen Pharmaceuticals, Inc.

Cancer Therapy Collaboration with Lilly

Analyst briefing on Chi-Med's pharmaceutical R&D business on 9 October 2013

TR-1: Notification of major interest in shares

Director's Shareholding

Interim Results for the Six Months Ended 30 June 2013

Nutrition Science Partners announces initiation of NATRUL-4, the maintenance study of the global Phase III trial for HMPL-004

Blocklisting Six Monthly Return

Initiation of Volitinib China Phase I study triggers US$5 million milestone payment

Notice of Announcement of 2013 Interim Results

Results of Annual General Meeting

Nutrition Science Partners announces initiation and treatment of the first Ulcerative Colitis patient in the global NATRUL Phase III trial for the novel botanical oral drug HMPL-004